To The Moon

Hello everyone! Today I want to share some trading strategies with you!1. $S&P 500(.SPX)$ up 40 from the lows, if it holds 5038 we can see 5100 by next week. Price action looks better here after basing above 5038 past hour $NVIDIA Corp(NVDA)$ back through 850... 867 in play tomorrow as long as it closes above 850 today $Coinbase Global, Inc.(COIN)$ up 13 into earnings.. 250+ coming this month2.Mastering your mindset is the key to becoming a successful trader ✅ - When the right opportunities arise, DON'T hesitate. - When a trade fails, FOLLOW your stop loss. - When times are tough, NEVER give up Your mindset is one of your greatest assets. Harness it and you

After Fed Chair has commented that rate hike might not be in the horizon, and we saw oil futures and the yield on the 10-year Treasury note were lower. Gold prices rose. The U.S. dollar lost ground to the euro and yen, but gained versus the pound. Most major cryptocurrencies traded lower. But what I would like to discuss in this article is how bond yields and gold are related and how we can plan our investing and trading strategy around it. Bond Yields and Gold Positive Relationship Not Confirmed? If we were to take a look the relationship between Gold and the bond market, there is not really confirmation of a positive relationship. The chart below presents the price of gold and the 10-year Treasuries (we took the yields and inverted them). As one can see, the price of gold was rising

I opened 10.0 share(s) $Amazon.com(AMZN)$ ,Buying more Amazon before the earnings call

With Rinvoq and Skyrizi, these new anti-inflammatory drugs, taking over the throne from Humira, $AbbVie(ABBV)$ has increased its full-year profit forecast in 2024.AbbVie now expects adjusted earnings per share to range from $11.13 to $11.33, exceeding the previous high of $11.17 per share, according to a statement Friday.Abbvie shares fell 1.3% at the start of trading in New York. As of Thursday's close, the stock had risen 8%. The company has been working to fill the void left by Humira after it lost patent protection last year and cheaper biosimilars began eating into market share.Abbvie's new biologic drugs like Skyrizi and Rinvoq have been helping to offset the impact of declining Humira sales. And the company's recent deals in cancer and neur